Accelerate to discover
Related topics
Introducing Celloger Mini: Automated and compact Live cell imaging inside your incubator
Jul 23, 2021
Celloger Mini is an automated live cell imaging system based on bright-field microscopy with fully motorized stages.
High quality Bioluminescence and X-Ray analysis in lung squamous cell carcinoma
Jul 21, 2021
Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence, fluorescence and X-Ray for in vivo...
Introducing IZON Exoid: accurate analysis of nanoparticles from 1 to 1000 nm
Jul 7, 2021
The IZON Exoid is the only standardisable method of measuring the entire nano range (1–1000 nm).
Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles
Jun 23, 2021
Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma. BEZ235 is an effective dual...
Microvascular injury in mild traumatic brain injury accelerates alzheimer-like pathogenesis in mice
Jun 22, 2021
Traumatic brain injury (TBI) is considered as the most robust environmental risk factor for Alzheimer’s disease....
Quantitative two-photon microscopy imaging analysis of human skin
Jun 21, 2021
Transdermal skin delivery is a method to transport various topical formulations to a deeper skin layer non-invasively....
Elevated NSD3 histone methylation activity drives squamous cell lung cancer
Jun 8, 2021
This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that...
A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic
Jun 3, 2021
Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest quality and precision and...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
